Type 2 Diabetes Mellitus: KOL Insight

June 2015 | | ID: T5FEE3C1D23EN
FirstWord

Abstracts

The market for Type 2 Diabetes therapies is extremely crowded. Several classes, including oral and injectable therapies, are all vying for market share. Differentiation remains a critical challenge. What do companies need to do to find a profitable position in the market for new products?

Type 2 Diabetes: KOL Insight is a comprehensive report that reveals the insights and opinions of 12 leading US and European KOLs. How they view the clinical benefits of marketed and late stage pipeline products, the administration and dosing issues that influence patient decisions and the non-clinical pressures that determine product choice are fully and frankly explored.

Expect evolution not revolution in the Type 2 Diabetes market. The battle will be won by those who bring superior efficacy and safety, innovative drug delivery technologies, novel drug combinations and patient friendly dosing. Pricing also remains an issue, particularly when only marginal therapeutic advances are being seen. Even if clinicians want to use certain products, payers and patients are often saying no. Finding market voice in such a competitive market environment demands a deep understanding of the clinical, patient and payer pressures that influence prescribing decisions and availability in formularies. Gain key KOL insights in Type 2 Diabetes: KOL Insight.

Answers to Critical Questions

• SGLT-2 inhibitors look set to replace DPP-4 inhibitors in the second line add on setting: what do KOLs see as the clinical benefits and what safety concerns remain?
• AstraZeneca’s Bydureon, GSK’s Tanzeum and Eli Lilly’s Trulicity are locked in battle for dominance in the once weekly GLP-1 agonist sector: how do KOLs rate their competing benefits and what improvements could help them to challenge Novo Nordisk Victoza’s current leadership in this drug class?
• Why is a SGLT-2/GLP-1 drug combination attractive to KOLs?
• There is much excitement about Novo Nordisk oral GLP-1 agonist semaglutide: are KOLs persuaded by the latest Phase II clinical data and how could this revolutionise the GLP-1 agonist market?
• Will Mannkind’s/Sanofi’s inhaled insulin Afrezza ever experience market acceptance and what changes to the products market positioning do KOLs suggest?
• KOLs expect price to play critical role in the success and uptake of Eli Lilly’s biosimilar insulin glargine Abasaglar, but what else must the company focus on in order to gain traction in the market and can Sanofi defend Lantus revenues?

Key Benefits

• Understand opinions of KOLs and formulate effective strategies for product positioning, pricing and clinician messaging
• Map new treatment options to Type 2 Diabetes patients and patient sub groups and identify niche opportunities
• Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions and placement in the treatment algorithm
• Appreciate the growing clinician discontent with drug prices and the negative effect it is having on patients – action now could disrupt the market and bring commercial benefit
• Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and why
• Evaluate the changing and challenging competitive landscape as wider clinical adoption and experience with new products impacts prescribing habits

Top Takeaways

• Detailed opinions of leading front line clinicians on current and late stage Type 2 Diabetes therapies and what they see as the critical advantages/disadvantages affecting their decision to prescribe
• Drug delivery, dosage and formulation factors affecting the Type 2 Diabetes sector
• New combination therapies that may fit into the treatment paradigm and the products that will be positively or adversely affected
• KOL attitudes on important clinical trials such as CANVAS, SAVOR, EXAMINE, TECOS, EMPA-REG OUTCOME, LEADER, IMAGE, CREDENCE and SUSTAIN

Features of the report

• Knowledgeable real world opinions of leading US and European KOLs that is not available in any other report
• Detailed and candid views on the future positioning and competitiveness of all current and upcoming Type 2 Diabetic therapies
• Essential insights which answer critical business questions and provide a platform for action and engagement.

Detailed KOL Views

• Glucagon-like peptide-1 (GLP-1) agonists)
• Lyxumia (lixisenatide once daily; Sanofi)
• Eperzan/Tanzeum (albiglutide once-weekly; GSK)
• Trulicity (dulaglutide once-weekly; Eli Lilly)
• Pipeline therapies
• Semaglutide (OG217SC; Novo Nordisk)
• LixiLan (lixisenatide/insulin glargine; Sanofi)
• Dipeptidyl Peptidase-4 (DPP-4) inhibitors
• Onglyza (saxagliptin; AstraZeneca)
• Nesina (alofliptin; Takeda)
• Tradjenta/Trajenta (linagliptin; Boehringer Ingelheim)
• Pipeline therapies
• MK-3102 (omarigliptin; Merck & Co.)
• Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
• Farxiga/Forxiga (dapaglifozin; AstraZeneca/BMS)
• Invokana (canaglifozin; J&J)
• Jardiance (empaglifozin; Boehringer Ingelheim/Eli Lilly)Pipeline therapies
• Synjardy (empagliflozin/metformin; Boehringer Ingelheim)
• PF04971729 (ertugliflozin; Pfizer/Merck & Co.)
• SaxaDapa (saxagliptin/dapagliflozin; AstraZeneca)
• Insulin therapy
• Tresiba (insulin degludec; Novo Nordisk)
• Toujeo/Optisulin (insulin glargine; Sanofi)
• Xultophy/IDegLira (insulin degludec/liraglutide; Novo Nordisk)
• Ryzodeg (insulin degludec/insulin aspart; Novo Nordisk)
• Afrezza (insulin human; Sanofi/Mannkind)
• Pipeline therapies
• LY2605541 (Insulin peglispro; Eli Lilly)
• NN1218/FIAsp (Insulin aspart; Novo Nordisk)
• Insulin biosimilars
• Abasaglar (insulin glargine; Eli Lilly/Boehringer Ingelheim)

Key Opinion Leaders

KOLs from North America

• John E Anderson, Chair, Department of Medicine, The Frist Clinic, Tennessee
• George Grunberger, Clinical Professor, Internal Medicine and Molecular Medicine & Genetics Chairman, Grunberger Diabetes Institute; Professor, Internal Medicine, Oakland University
• William Beaumont School of Medicine; Clinical Professor of Internal Medicine and of Molecular Medicine & Genetics, Wayne State University School of Medicine, Michigan Silvio Inzucchi, Professor of Medicine (Endocrinology); Clinical Director, Section of Endocrinology; Director, Yale Diabetes Center; Director, Endocrinology & Metabolism Fellowship; Director, Yale Affiliated Hospitals Program, Yale School of Medicine, Connecticut
• Etie Moghissi, Associate Clinical Professor of Medicine, UCLA David Geffen School of Medicine, California
• Jay S Skyler, Professor of Medicine, Pediatrics & Psychology, Division of Endocrinology, Diabetes, & Metabolism, University of Miami, Florida
• Joel Zonszein, Professor of Clinical Medicine, Albert Einstein College of Medicine Department of Medicine, Division of Endocrinology and Metabolism, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, New York

KOLs from Europe

• Prof Geremia Bolli, Professor of Internal Medicine, Head and Chief of the Internal Medicine, Endocrine and Metabolic Sciences Clinic, Endocrinology and Metabolism, University of Perugia, Italy
• Prof Antonio Ceriello, Head, Research Department, Diabetes & CVD, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain
• Prof Bernard Charbonnel, Professor of Endocrinology and Metabolic Diseases, University of Nantes, France
• Jens Juul Holst, Professor of Medical Physiology; Chairman, Faculty’s Research Center for Diabetes and Obesity Endocrinology Research Section, Faculty Of Health Sciences, University of Copenhagen, Denmark
• Prof John Wilding, Professor of Medicine & Honorary Consultant Physician, Obesity and Endocrinology Clinical Research, Institute of Ageing & Chronic Disease, Clinical Sciences Centre, University Hospital Aintree, UK
• Anonymous KOL, Germany

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, June 2015.

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH OBJECTIVES

3. RESEARCH FOCUS

3.1. Epidemiology
3.2. Diabetes prevalence
3.3. Diabetes cost burden
3.4. Type 2 diabetes treatment

4. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS

4.1. Overview
4.2. Recently marketed drugs
4.3. GLP-1 agonists (Lyxumia, Tanzeum/Eperzan, Trulicity)
4.4. Pipeline drugs
4.5. Semaglutide (OG217SC; Novo Nordisk)
4.6. LixiLan (Lixisenatide/Insulin glargine; Sanofi)

5. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS

5.1. Overview
5.2. Recently marketed drugs
5.3. DPP-4 inhibitors (Onglyza, Nesina/Vipidia, Tradjenta/Trajenta)
5.4. Pipeline drugs
5.5. MK-3102 (Omarigliptin; Merck & Co.)

6. SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT-2) INHIBITORS

6.1. Overview
6.2. Recently marketed drugs
6.3. SGLT-2 inhibitors (Farxiga/Forxiga, Invokana, Jardiance)
6.4. Pipeline drugs
6.5. Synjardy (Empagliflozin/Metformin; Boehringer Ingelheim)
6.6. PF04971729 (Ertugliflozin; Pfizer/Merck & Co.)
6.7. SaxaDapa (Saxagliptin/Dapagliflozin; AstraZeneca

7. INSULIN THERAPY

7.1. Overview
7.2. Recently marketed drugs
7.3. Tresiba (Insulin degludec; Novo Nordisk)
7.4. Toujeo/Optisulin (Insulin glargine; Sanofi)
7.5. Xultophy/IDegLira (Insulin degludec/liraglutide; Novo Nordisk)
7.6. Ryzodeg (Insulin degludec/insulin aspart; Novo Nordisk)
7.7. Afrezza (Insulin human; Sanofi/Mannkind)
7.8. Pipeline drugs
7.9. LY2605541 (Insulin peglispro; Eli Lilly)
7.10. NN1218/FIAsp (Insulin aspart; Novo Nordisk)

8. INSULIN BIOSIMILARS

8.1. Overview
8.2. Pipeline drugs
8.3. Abasaglar (insulin glargine; Eli Lilly/Boehringer Ingelheim)

9. CONCLUSION

9.1. Current and future treatment algorithm

10. APPENDIX

10.1. KOL biographies
10.2. KOLs from North America
10.3. KOLs from Europe